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NEONATAL RESPIRATORY DISTRESS SYNDROME AS A FUNCTION OF 
GESTATIONAL AGE AND THE LECITHIN/SPHINGOMYELIN RATIO 
Caryn M. St. Clair, Jessica L. Illuzzi, and Errol R. Norwitz.  Section of Maternal-Fetal 
Medicine,  Department of Obstetrics, Gynecology & Reproductive Sciences,  
Yale University School of Medicine, New Haven, CT. 
 
 This study was designed to derive predictive logistic regression equations to allow the 
risk of neonatal respiratory distress syndrome (RDS) to be defined as a function of both 
the lecithin/sphingomyelin (L/S) ratio and gestational age.  We hypothesize that the 
optimal cutoff value will vary significantly depending on gestational age, and that our 
data will support the need to account for gestational age when interpreting test results.   
 Data was collected via a retrospective chart review.  Women who underwent 
amniocentesis for the purpose of assessing fetal lung maturity at Yale-New Haven 
Hospital from 1998 to 2004 were identified and included if delivery of a liveborn, 
singleton, non-anomalous infant occurred within 72 hours of the lecithin/sphingomyelin 
ratio assay.  Maternal and neonatal data were collected regarding demographics, 
pregnancy complications and neonatal outcomes, including respiratory distress syndrome. 
 A total of 210 mother-neonate pairs met criteria for analysis, with 8 cases of RDS.  
Both gestational age and L/S ratio were independent predictors of RDS.  By modeling the 
odds of RDS using logistic regression, a probability of RDS approximating 10% was 
noted at an L/S cutoff of 3.6 at 32 weeks, 2.8 at 34 weeks, 1.8 at 36 weeks, and 1.4 at 
term.  Under 32 weeks of gestation a probability as low as 10% was not observed by this 
model.  We conclude that stratifying risk of neonatal RDS using both the L/S ratio and 
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Introduction 
Definition and Epidemiology of Neonatal Respiratory Distress Syndrome: 
 Respiratory distress syndrome (RDS), also known as hyaline membrane disease 
(HMD), refers to respiratory compromise presenting at or shortly after delivery due 
specifically to a deficiency of pulmonary surfactant.  Though this deficiency was 
originally described by Avery and Mead in 1959 (1), RDS remains a serious, frequently 
fatal, neonatal complication.  Neonatal RDS affects approximately 1% of all live births 
(2-4); however, not all infants are at equal risk. The pulmonary system is among the last 
of the fetal organ systems to become functionally mature. As such, RDS is primarily – 
although not exclusively – a disease of premature infants with an incidence and severity 
that is highly dependent upon gestational age (2-5).    
A recent epidemiological study estimated that there are approximately 80,000 cases 
of neonatal respiratory failure per year in the United States and roughly 8,500 deaths, 
with a hospital cost totaling $4.4 billion (6).  The 80,000 cases – representing 2% of all 
live births – were evenly distributed over three weight classes: very low birth weight (< 
1,500 g), low birth weight (1,500 – 2,499 g), and normal birth weight (> 2,500 g).  Thus, 
while prematurity and low birth weight have been associated with a higher risk for RDS, 
normal birth weight babies accounted for 1/3 of cases of neonatal respiratory failure.  
Neonates with very low birth weight, however, accounted for half of all deaths.   
 
History of Neonatal Respiratory Distress Syndrome: 
The documented history of respiratory distress syndrome dates back to the early 
twentieth century, when pulmonary hyaline membrane (PHM) was described and 
 2
considered by Hochheim to represent aspirated amniotic fluid.  This theory was relatively 
accepted until the early 1950’s when radiographic descriptions of the reticulogranular 
pattern in generalized neonatal atelectasis were distinguished from the radiographic 
appearance in cases of aspirated amniotic debris (7).  Work at that time by Pattle, 
Clements and Brown had begun to show that a low surface tension in the lung was 
imperative for proper lung function.  But it wasn’t until Avery and Mead’s publication in 
1959 that the clinical relevance of these findings was fully understood.   
In their paper Surface Properties in Relation to Atelectasis and Hyaline Membrane 
Disease (1), Avery and Mead provided evidence that the lungs of neonates with hyaline 
membrane disease lack the alveolar material – a “surface-active substance” – responsible 
for maintaining a low surface tension.  Experimenting on lung extracts, they showed that 
the lowest surface tension values in neonates 1,100 to 1,200 grams were 20-30 dynes/cm, 
while the lowest tensions in heavier infants, older children and adults were all under 20 
dynes/cm, and more commonly 5-7 dynes/cm.  Notably, heavier infants with hyaline 
membrane disease were the only exception and fell into the former category with tensions 
of 20-30 dynes/cm, and generally above 30 dynes/cm. 
Work by Adams and Fujiwara continued along this line.  They were able to determine 
by thin-layer chromatography that the active components of the surface-active substance 
were predominantly that of lecithin and sphingomyelin.  Further study showed that 
“without exception, lungs with poor surface activity contained considerably less total 
lipid, less total phospholipid, and a reduced percentage of lecithin” (8).  This also 
indicated that the dysfunction in the lungs of premature infants and infants with HMD 
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was due to a decreased quantity of these active components rather than deactivation or 
decreased quality of the lipids. 
 
Surfactant – Composition and Normal Physiology: 
Research to elucidate the composition of surfactant – a term derived from “surface-
active agent” – has been ongoing over the last several decades and has shown that 
surfactant is comprised mainly of lipids and proteins similar to a cell membrane (7).  
Lipids make up approximately 90% of pulmonary surfactant, half of which is dipalmitoyl 
phosphatidylcholine (DPPC); this lipid portion conveys the surface-active properties of 
surfactant (9).  Phosphatidylcholines are the second most common lipid component, 
specifically phosphatidylglycerol, followed by cholesterol and anionic phospholipids.   
The remaining 10% of pulmonary surfactant is comprised of proteins.  While plasma 
proteins such as albumin and secretory IgA make up around half of the protein 
composition, apoproteins (SP-A, SP-B, SP-C and SP-D) make up the remainder (9).  SP-
A and SP-D are large, water soluble proteins belonging to the collectin family that 
participate in both innate immunity and the metabolism of surfactant.  The smaller 
apoproteins, SP-B and SP-C, are hydrophobic intrinsic membrane proteins that facilitate 
formation of the monolayer, speeding the rate at which surfactant moves into the air-
water interface to form a stable film (7, 9). 
Synthesis and secretion of surfactant occurs predominantly within cuboidal type-II 
alveolar cells.  Lipids enter these cells via the bloodstream, while the pneumocytes use 
the secretory pathway to synthesize the various apoproteins.  Lamellar bodies act as the 
site for final assembly, and the resulting pulmonary surfactant is secreted from the cells 
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via constitutive exocytosis (9).  Surfactant levels are low until just prior to delivery, when 
increased synthesis is triggered by a surge in glucocorticoids, as well as other factors 
such as thyroid hormone, thyroid-releasing hormone, prolactin, and the growth-factor 
EGF.  Cortisol acts by increasing the differentiation of type-II pneumocytes and the 
formation of lamellar bodies within the fetal lungs, stimulating surfactant production and 
thereby lung maturation (9). 
Physiologically, pulmonary surfactant serves three main functions.  First and 
foremost, it increases the compliance of the lungs by decreasing surface tension.  By 
decreasing the tendency for elastic recoil, it allows the neonate to expand the lungs 
without exerting extreme effort and prevents collapse of the alveoli at end expiration.  
Second, surfactant decreases the amount of fluid accumulation in the alveoli by 
preserving the tendency for fluid movement into the interstitium.  Without surfactant, the 
increased surface tension collapses the alveolus, disturbs Starlings forces across the 
alveolar wall, and increases fluid movement into the alveoli, resulting in pulmonary 
edema.  Finally, the presence of surfactant maintains the equality of alveolar size during 
the respiratory cycle, preserving uniform surface area and maximizing gas diffusion and 
ventilation throughout the pulmonary apparatus (9). 
 
Pathology & Pathophysiology of Neonatal Respiratory Distress Syndrome: 
 Though respiratory distress in the newborn can have many etiologies – for example, 
maternal sedation, fetal head injury during delivery, aspiration, or hypoxia due to a 
nuchal cord – the most common cause is respiratory distress syndrome (10).  The 
fundamental defect in this disorder is a deficiency of pulmonary surfactant, which leads 
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to increased surface tension in the alveoli as described above.  The lungs are stiff and 
tend to collapse further with each breath, causing atelectasis; this effect is worsened by 
the soft thoracic wall that is pulled inward with inspiration.  Resultant hypoventilation 
and poor perfusion cause the newborn to become hypoxemic and to retain carbon dioxide, 
leading to a respiratory acidosis.  The pulmonary vasculature vasoconstricts, causing 
further hypoperfusion and ventilation/perfusion (V/Q) mismatch.  Both endothelial and 
epithelial damage lead to leakage of a protein-rich, fibrin-rich exudate into the alveolar 
spaces; this exudate accumulates with the necrotic cells and forms hyaline membranes.  
These membranes act to increase the diffusion gradient across the alveoli, creating a 
barrier to gas exchange and worsening the acidosis and hypoxemia.  These factors further 
impair surfactant synthesis and the cycle continues, severely impairing lung function in 
the neonate and increasing the likelihood of complete respiratory failure (10). 
 On gross pathology, the lungs of infants with RDS may be of normal size, but are 
solid and airless; they generally sink when placed in water.  They have a darker 
appearance than healthy lungs, commonly a reddish purple resembling the liver.  The 
alveoli are poorly developed, and most are collapsed.  Eosinophilic hyaline membranes 
composed of necrotic cellular debris, fibrinogen and fibrin, line the respiratory 
bronchioles, alveolar ducts and alveolar spaces.  Inflammatory cells such as neutrophils 
are generally absent from these membranes; the cell debris is mostly comprised of 
necrotic type-II pneumocytes (10). 
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Diagnosis of Neonatal Respiratory Distress Syndrome: 
RDS is diagnosed based on clinical and radiological findings.  The classic clinical 
signs of neonatal RDS include tachypnea, nasal flaring, chest retractions, and expiratory 
grunting (11, 12).  These findings generally appear immediately after delivery or within 
the first few hours of life.  Tachypnea is the newborn’s attempt to increase minute 
ventilation to compensate for a decreased tidal volume.  The relatively frequent finding of 
nasal flaring represents an effort to decrease the resistance in the upper airway, while 
retractions indicate an effort to increase negative intrapleural pressure to inflate the lungs.  
As the neonate tries to maintain end-expiratory lung volume, he may expire against a 
closed glottis, resulting in the audible grunting sounds characteristic of infants with RDS.  
More worrisome signs of neonatal respiratory distress include cyanosis, gasping, choking, 
and apnea (11).  Physical examination often aids the diagnosis.  Auscultation may reveal 
poor air exchange and/or fine rales, and observation may reveal the use of accessory 
muscles during inspiration as well as episodes of apnea (12). 
Chest radiographs at birth and at regular intervals can be helpful in establishing this 
diagnosis as well and can often allow differentiation between transient tachypnea of the 
newborn (TTN) and respiratory distress syndrome (RDS).  Unlike RDS, TTN is not the 
result of an underdeveloped pulmonary surfactant system; instead it represents delayed 
clearance of fetal lung fluid and a transient pulmonary edema (11).  It presents clinically 
as a milder form of RDS, but it is generally self-limited and resolves more rapidly.  The 
chest x-ray in TTN reveals increased pulmonary interstitial markings, fluid in the 
interlobar fissures, and occasionally a pleural effusion or alveolar edema (11).  This 
differs from the chest radiograph in RDS, which shows decreased lung volumes, domed 
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diaphragms, air bronchograms, and a diffuse reticular-granular opacification or ground-
glass appearance that may progress to total white-out of the lung fields (12).  It is 
important to account for the degree of prematurity, as well as positive pressure ventilation 
or surfactant administration, which can alter the appearance and degree of pathology in 
the chest film.   
 
Treatment of Neonatal Respiratory Distress Syndrome: 
 Treatment of neonatal RDS is based on interventions that occur in the prenatal, 
perinatal and postnatal periods.  Given the close relationship between RDS and 
gestational age (3-5), the most effective way to prevent RDS is to prevent prematurity by 
delaying delivery, thereby prolonging gestation (12).  Performing antenatal testing for 
fetal lung maturity and administering antenatal corticosteroids to women at risk for 
preterm delivery are additional means for reducing the risk of neonatal RDS prenatally.  
Options for antenatal fetal lung testing for prediction of RDS will be discussed separately. 
 
Antenatal Corticosteroids: 
The effect of steroids was first observed by Liggins in 1969 while experimenting with 
sheep given antenatal dexamethasone (13); he noted that the lungs of their premature 
lambs – delivered at a point where the lungs would not be expected to be aerated – were 
partially inflated.  Three years later Liggins and Howie published the first randomized 
control trial of antenatal administration of betamethasone in humans, showing that both 
respiratory distress syndrome and early neonatal mortality were significantly reduced in 
the treated group compared to controls (14).  Subsequent studies have supported their 
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conclusions that antenatal steroid treatment improves overall pulmonary status, increases 
neonatal survival, and decreases the incidence and severity of RDS (12, 15, 16).  A 2006 
meta-analysis of twenty-one studies confirmed a significant reduction not only in 
neonatal death and RDS, but also in intraventricular hemorrhage, necrotizing enterocolitis, 
intensive care admissions, respiratory support, and systemic infections in the first 48 
hours of life; the authors concluded that a single course of antenatal corticosteroids 
should be routine care in preterm deliveries with few exceptions (17). 
The morbidity and mortality associated with neonatal RDS increase significantly with 
perinatal asphyxia (12).  Therefore in the perinatal period, management of RDS is largely 
aimed at reducing the risk of asphyxiation and stress to the infant; an experienced 
resuscitation team led by a neonatologist or pediatric intensivist is highly recommended if 
the neonate is at high risk for respiratory distress. 
 
Surfactant Replacement: 
 Though many interventions play a role in the immediate postnatal management of 
RDS – correction of acidosis, maintenance of a neutral thermal environment, correction 
of hypovolemia and hypotension, maintenance of electrolyte balance, continuous 
monitoring, and control of infection (12) – respiratory support and surfactant replacement 
remain the cornerstones of therapy.  Once Avery and Mead determined that hyaline 
membrane disease was the result of a deficiency in surfactant (1), efforts were undertaken 
to replace the surface-active agent.  Initial attempts centered on administration of an 
aerosol form of the active phospholipid in natural surfactant, dipalmitoyl 
phosphatidylcholine (DPPC); unfortunately, this approach was not found to be effective 
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at treating RDS (18).  The first successful surfactant replacement took place in 1980 
when Fujiwara et al. administered artificial surfactant from cow lungs endotracheally to 
infants with severe hyaline membrane disease; results showed an overall improvement in 
oxygenation, a decrease in respiratory support requirements, resolution of radiographic 
lung changes, and reversal of acidosis and systemic hypotension (19).  Prospective, 
randomized controlled trials followed, confirming that administration of artificial 
surfactant in the immediate postnatal period decreased the severity of respiratory distress 
in the first days of life (20, 21).   
 Evidence has continued to demonstrate a decrease in morbidity, mortality, and use of 
resources with the advent of surfactant replacement (22-24), and attention has turned to 
comparison of timing, dosage, and type of preparation of the surfactant.  Studies have 
indicated that animal-derived, natural preparations are more effective at treating RDS, 
and convey lower mortality than their synthetic counterparts lacking a protein component 
(24, 25); however, recent randomized controlled trials of a new class of synthetic 
surfactants containing a peptide analog of SP-B have shown promising results with 
similar efficacy and mortality to the natural preparations (26, 27).  Literature regarding 
the timing of surfactant administration indicates that early administration and shorter 
duration of mechanical ventilation is advantageous compared to delayed administration 
and a longer period of time spent on the ventilator (28-31). 
 
Prediction of Neonatal Respiratory Distress Syndrome: 
 Given the gravity of neonatal respiratory distress syndrome and its complications, 
prediction of fetal lung maturity or lack thereof prior to delivery has been a heavily 
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researched topic.  To assist obstetric care providers in counseling pregnant women at risk 
of preterm delivery, a series of tests have been developed in an attempt to predict 
gestational age-related risk of developing RDS (2).  These can be divided into indirect, 
direct biochemical, and direct biophysical tests.  Indirect tests involve determination of 
the gestational age or size of the fetus in order to infer maturity and pulmonary status; 
these include calculation of the last menstrual period, appearance of fetal heart tones, 
identification of the gestational sac on ultrasound, measurement of crown-rump length 
and biparietal diameter.  Direct biochemical tests measure the concentration of various 
components of pulmonary surfactant secreted by the fetal lungs into the amniotic fluid, 
and include measurement of the lecithin/sphingomyelin (L/S) ratio and the 
phosphatidylglycerol (PG) band.  Direct biophysical tests evaluate the surface-active 
properties of the phospholipids in pulmonary surfactant and include the foam stability 
index (FSI), fluorescence polarization (TDx-FLM), and the lamellar body count (LBC). 
 
Lecithin/Sphingomyelin Ratio: 
 Introduced by Gluck and others at Yale University in 1971, the L/S ratio was the first 
widely accepted test available for assessment of fetal lung maturity (32).  This assay is 
based on the observation that pulmonary secretions from the lungs of the fetus flow into 
the amniotic fluid, affecting the phospholipid concentrations.  Lecithin and 
sphingomyelin are present in relatively equal amounts until 32 to 33 weeks of gestation, 
at which point the lecithin level begins to rise appreciably.  Gluck observed that neonatal 
respiratory distress syndrome was uncommon after the lecithin/sphingomyelin ratio had 
reached 2.0, which occurs around 35 weeks of gestation in uncomplicated pregnancies 
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(32, 33).  This value has remained an accepted threshold for the determination of fetal 
pulmonary status in nondiabetic women; however it is suggested that the value be 
correlated with clinical outcomes at individual centers, as the variation between 
laboratories can be considerable (2).   
 One disadvantage of the L/S ratio is that it can be difficult to perform and interpret 
and is not readily available at all institutions (34).  The sample must be handled 
appropriately during transport and while awaiting analysis, and the test itself is labor 
intensive, taking 3-5 hours.  Additionally, the presence of blood or meconium in the 
sample – common contaminants – affects the validity and utility of the result (35).  The 
L/S ratio has been studied against other assays for fetal lung maturity that have been 
developed over the years, and those comparisons are discussed in the following sections. 
 What is needed to improve obstetric care is not an innovation in biochemical assays 
and techniques, however, but rather an improved understanding of the probability of a 
fetus developing RDS for a given test value at a specific gestational age (36, 37).  Ghidini 
et al. reported significant morbidity in a study of preterm infants with mature lung indices, 
including a 12% incidence of neonatal RDS (38).  Gestational age-specific risk 
stratification cutoffs for RDS have been developed for other assays of fetal pulmonary 
maturity (39-41); a similar approach must be taken for the L/S ratio, a test frequently 




 Phosphatidylglycerol is a minor constituent of surfactant; its concentration in the 
amniotic fluid tends to increase most appreciably several weeks after the rise in lecithin 
occurs (42).  Measured by thin-layer chromatography, presence of a PG band generally 
represents a more advanced state of fetal pulmonary status, as PG serves to enhance the 
spread of phospholipids along the alveolar surface (2).  The advantage to PG analysis is 
that it is not affected by common contaminants, such as blood or meconium (2, 43); 
therefore, it is a good test in patients who have experienced rupture of membranes and 
can provide a vaginal pool sample.  The disadvantage remains that the sensitivity of PG 
on thin-layer chromatography varies, so the significance of its absence also varies (35).  
In other words, the PG band often becomes “positive” relatively late in pregnancy, and 
when used alone may suggest fetal lung immaturity at later gestational ages when the risk 
of neonatal RDS is low (44). 
 
Foam Stability Index: 
 The foam stability test, or “shake test,” was described by Clements et al. in 1972 (45).  
In this test, addition of ethanol to amniotic fluid eliminates any foam formed by non-
surfactant substances (2).  If after shaking the tube a stable foam remains, then surface-
active components of surfactant are present in the amniotic fluid; serial dilutions with 
ethanol allow quantification of the surfactant concentration.  This test has since been 
modified and is now referred to as the foam stability index, or FSI   (46).  The value of 
the index represents the highest ethanol volume fraction that permits the formation of 
 13
stable foam after vigorously shaking a mixture of ethanol and amniotic fluid; the 
accepted cutoff for fetal lung maturity is greater than or equal to 47.   
 
Fluorescence Polarization: 
One of the most widely used tests for fetal lung maturity is the TDx-FLM II 
surfactant-to-albumin assay (Abbott Laboratories, Abbott Park, IL), which uses 
fluorescence polarization to determine the relative concentrations of surfactant and 
albumin in amniotic fluid; results are given as mg of surfactant per 1 g of albumin.  An 
elevated ratio greater than 55 mg/g has been used as a cutoff to indicate fetal lung 
maturity (2, 47), although one study suggested that this threshold be lowered to 45 mg/g, 
maintaining a sensitivity of 100% and a specificity of 90% (3).  Again however, the 
dichotomous, “positive” or “negative” approach to biochemical assays for fetal lung 
maturity can be fundamentally misleading, and attempts have been made to account for 
gestational age when interpreting test results.  A number of studies have used logistic 
regression to show the probability of RDS based on the TDx-FLM value as well as 
gestational age (39-41).  In general, a higher threshold value is required at lesser 
gestational age, while a lower, more borderline value may be acceptable at later 
gestational age. 
The TDx-FLM surfactant-to-albumin ratio has performed similarly to the L/S and PG 
assays in terms of prediction of neonatal RDS (48).  Advantages of the TDx-FLM II 
assay are that it is a rapid test that is relatively easy to perform and highly reproducible.  
The disadvantage remains that blood and meconium contamination can interfere with 
interpretation of the results (2). 
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Lamellar Body Count: 
 Lamellar body count (LBC) is a newer technique being utilized to assess fetal lung 
maturity.  Final assembly and storage of surfactant occurs within lamellar bodies, which 
are extruded from type-II pneumocytes into the alveoli (2, 9); lamellar body count is, 
therefore, a relatively direct measurement of surfactant production.  While some studies 
have cited values of 30,000 per microliter as the lower limit for indication of fetal lung 
maturity (2, 49), a recent consensus of protocol by Neerhof et al. reported that values 
over 50,000 per microliter were more suggestive of pulmonary maturity, while values 
under 15,000 per microliter were indicative of pulmonary immaturity (50).  Ventolini and 
colleagues studied neonatal outcomes before and after this change in threshold, and 
concluded that the higher cutoff value of 50,000 per microliter resulted in significantly 
decreased neonatal morbidity and complication rates (51).  Efforts have again been 
undertaken, however, to create gestational age-specific risk predictions for this assay to 
replace dichotomous cutoff values (52). 
 Lamellar body count has been shown to perform as well or better than the PG, the L/S 
ratio, and the TDx-FLM assay (52-54).  LBC conveys many advantages; it is faster, more 
objective, less labor intensive, less technique dependent, and less expensive than both PG 
and L/S analysis (53).  Furthermore, the similar size of lamellar bodies and platelets 
allows the LBCs to be conducted on a standard Coulter counter, available in all hospital 
laboratories.  Some authors suggest that lamellar body count replace the 
lecithin/sphingomyelin ratio for prediction of fetal lung maturity and risk of neonatal 
RDS given these considerations (49, 54).  However the L/S ratio remains the oldest, most 
studied index for fetal pulmonary status, and continues to be the test of choice in many 
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institutions.  Given this, gestational age-specific L/S cutoff values to predict neonatal 





















Statement of Purpose 
 This study was designed to derive predictive logistic regression equations to allow the 
risk of neonatal respiratory distress syndrome (RDS) to be defined as a function of both 
the lecithin/sphingomyelin (L/S) ratio and gestational age.  We hypothesize that the 
optimal cutoff value for this assay’s prediction of RDS will vary significantly depending 
on gestational age, and that our data will support the need to account for gestational age 
when interpreting these test results.  Secondarily we will contribute data to describe the 

















Materials and Methods 
 An application to conduct a medical record review for the purposes of this study was 
submitted to the hospital’s Human Investigations Committee, and the study was approved.  
Women who underwent amniocentesis for fetal lung maturity screening with the 
lecithin/sphingomyelin (L/S) assay at Yale-New Haven Hospital in New Haven, 
Connecticut, between June 1998 and December 2004 were identified.  Patients were 
included only if the lecithin/sphingomyelin ratio measurement was obtained within 72 
hours of delivery, and the delivery resulted in a singleton, liveborn infant without major 
congenital anomalies.  Maternal records from the above dates were requested and 
reviewed for gestational dating criteria, timing and results of the lecithin/sphingomyelin 
ratio testing, presence or absence of the phosphatidylglycerol (PG) band, date and time of 
delivery, type of delivery, maternal age and race, smoking status, presence or absence of 
diabetes, chronic hypertension, preeclampsia, and preterm premature rupture of 
membranes (PPROM), as well as antenatal corticosteroid status.  Neonatal records 
provided information on infant sex, birth weight, apgar scores, resuscitation effort at 
delivery, and disposition to the well baby nursery or the newborn special care unit 
(NBICU).  Those not meeting inclusion criteria were documented as excluded, and the 
cause for exclusion was noted; such mother-neonate pairs were not included in the final 
statistical analysis. 
Infants sent to the well baby nursery were assumed not to have respiratory distress 
syndrome or other major complications as those clinical entities would not be managed in 
this setting, and no further data was collected.  For those sent to the NBICU, data was 
collected regarding type and duration of oxygen requirement (intermittent mandatory 
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ventilation, nasal cannula, nasal continuous positive airway pressure), diagnoses of 
respiratory distress syndrome (RDS), transient tachypnea of the newborn (TTN), 
persistent pulmonary hypertension (PPH), bronchopulmonary dysplasia (BPD), 
pneumothorax (PTX), and other complications including retinopathy of prematurity 
(ROP), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), and sepsis at 
various points of admission.  The length of stay in the NBICU, as well as discharge with 
or without oxygen, was also noted. 
Gestational age was determined by last menstrual period confirmed by second-
trimester ultrasound, first trimester ultrasound, or in vitro fertilization or artificial 
insemination dating, as available.  Cases dated only by a second- or third-trimester 
ultrasound were excluded.  Maternal race was self-described in the medical record.  
Maternal diabetes was described by the White classification as documented in the 
medical record; diabetes in the study population was defined by any insulin requirement, 
including both insulin-dependent pregestational diabetes and insulin-requiring gestational 
diabetes.  Diet-controlled diabetes was noted separately.  Preeclampsia was defined as the 
presence of new-onset persistent hypertension (blood pressure 140 mm Hg or more 
systolic and/or 90 mm Hg diastolic) and new-onset proteinuria (300 mg or more urinary 
protein per 24 hours) after 20 weeks of gestation.  Chronic hypertension was defined by 
maternal antihypertensive use before pregnancy.  Maternal smoking status was identified 
in the medical record.  
Neonatal RDS, TTN, PPH, and BPD diagnoses were obtained via an existing 
database maintained by the Section of Perinatal Medicine in the Department of Pediatrics 
at Yale-New Haven Hospital.  Neonatal RDS – our primary outcome – was diagnosed by 
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the presence of at least 2 of the following 3 criteria: 1) evidence of respiratory 
compromise (tachypnea, retractions, and/or nasal flaring) shortly after delivery and a 
persistent oxygen requirement for more than 24 hours, 2) administration of exogenous 
pulmonary surfactant, and/or 3) radiographic evidence of neonatal pulmonary hyaline 
membrane disease as diagnosed by an attending pediatric radiologist or neonatologist.  
Radiographic evidence of neonatal RDS included atelectasis, air bronchograms, and a 
diffuse reticulogranular infiltrate.   
The data was analyzed using the SAS 9.1 statistical software package.  Maternal and 
neonatal characteristics were compared in infants with and without neonatal respiratory 
distress syndrome using Chi-square analysis as well as Fisher’s exact test.  The 
gestational age at the time of amniocentesis and the lecithin/sphingomyelin ratios were 
analyzed using the Student’s t-test; these values were compared in neonates with and 
without RDS by Pooled and Satterthwaite t-tests, after assessment of the equality of 
variances.  Wald odds ratios with 95% confidence intervals were determined for 
predictors of neonatal RDS; these values were also calculated after adjustment for 
gestational age.  Finally using multivariate logistic regression, a prediction equation for 
the probability of neonatal RDS was developed with both the lecithin/sphingomyelin 
ratio value and gestational age as the descriptive variables; step-wise backward 
elimination was used to eliminate other possible confounders, using the partial F test and 
testing for changes in parameter estimates of greater than 10%.  This equation is 
discussed further within the results. 
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Results 
 A total of 443 maternal charts identified by billing codes designating amniocentesis 
for fetal lung maturity within the study period were identified and screened for this study; 
210 mother-neonate pairs met criteria for analysis and were abstracted, while 233 were 
excluded.  The most common cause for exclusion was a time interval from amniocentesis 
to delivery greater than 72 hours, resulting in 158 exclusions (68%).  Nineteen subjects 
(8%) were eliminated based on absence of key data such as the lecithin/sphingomyelin 
ratio, while 20 subjects (9%) were excluded based on delivery at an outside hospital and 
lack of neonatal data.  Amniocentesis for genetic purposes and not for assessment of fetal 
lung maturity ruled out 11 subjects (5%), and multiple gestations accounted for 15 
exclusions (6%).  Seven maternal-neonate pairs (3%) were excluded because the mother 
was already represented in the database.  Finally three cases (1%) were excluded due to 
severe congenital malformations that could complicate the diagnosis of neonatal 
respiratory distress syndrome.   
 As indicated in Figure 1, sixty-five of the 210 included neonates (31%) went to the 
Newborn Intensive Care Unit (NBICU), while 145 neonates (69%) went to the well-baby 
nursery.  Those sent to the nursery were assumed not to have neonatal RDS, as oxygen 
support is not administered outside of the NBICU.  Of the included population of 210 
pairs, 8 cases of neonatal RDS were diagnosed, for an incidence of 3.8%.  An additional 
8 neonates were noted to have transient tachypnea of the newborn (TTN), also with an 
incidence of 3.8%.  One newborn had documented persistent pulmonary hypertension 
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Figure 1: Study Population 
  
Figure 2 displays the gestational age distribution of the patient population at the time 
of amniocentesis, which occurred within 72 hours of delivery.  In the population without 
RDS (n = 202), the mean gestational age was 36.5 ± 1.2 weeks, with a median of 36.6 
weeks (interquartile range: 35.9 - 37.3 weeks).  Interquartile range represents the 25th 
through 75th percentiles.  The lowest gestational age in the population without RDS was 
32.9 weeks, while the highest was 39.1 weeks.  In the population with RDS (n = 8), the 
mean gestational age was 32.6 ± 3.6 weeks, with a median of 33.1 weeks (interquartile 
range: 30.1 - 35.0 weeks).  The lowest gestational age in the population with RDS was 
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26.0 weeks, while the highest in this population was 37.4 weeks.  The difference in the 
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Figure #2: Gestational age distribution of the patient population.  Data represent gestational age 
at amniocentesis for fetal lung maturity; all samples were obtained within 72 hours of delivery. 
 
The incidence of RDS did decline with increasing gestational age.  While the 
incidence in the total population was 3.8%, the incidence of RDS was 80% (4/5) for 
deliveries at 32 weeks or less of gestation, 2.4% (3/127) between 33 and 36 weeks of 
gestation, and 1.3% (1/78) for deliveries at or after 37 weeks of gestation.  A univariate 
logistic regression equation was derived using this data, and the probability of neonatal 
RDS for each week of gestational age was determined.  Equation 2 shows Equation 1 
rearranged to solve for the probability of RDS:  























The results are shown in Figure 3a; similar studies of RDS and gestational age are plotted 
for comparison in Figure 3b.  It should be noted, however, that these studies may plot 
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Figure 3: The risk of neonatal RDS as a function of gestational age in our population (a) compared to 





In the population without RDS, the mean lecithin/sphingomyelin (L/S) ratio was 3.6 ± 
1.1, with a median of 3.5 (interquartile range: 2.8 - 4.0).  The lowest L/S value in the 
population without RDS was 1.4, while the highest was 8.5.  In the population with RDS, 
the mean L/S ratio was 1.8 ± 0.7, with a median value of 1.8 (interquartile range: 1.2 - 
2.3).  The lowest L/S value in the population with RDS was 1.0, while the highest was 
2.8.  The difference in mean L/S ratio between the two populations was statistically 
significant, P < 0.0001 
Table 1 presents the maternal clinical characteristics of the study population and their 
association with neonatal respiratory distress syndrome.  Within the limits of our study 
population, the categorical clinical characteristics of race, tobacco use, diabetes status, 
and presence or absence of hypertension and preeclampsia did not differ among maternal-
infant dyads who did and did not develop RDS.   
Other variables were also studied.  The mean maternal age for neonates without RDS 
was 31.0 years ± 6.0, while the mean maternal age for infants with RDS was 30.0 years ± 
9.9; this was not a significant predictors of neonatal RDS, with P = 0.78.  Only four cases 
of PPROM were documented in the study sample, one of those four cases resulting in a 
case of neonatal RDS; this was also found to be an insignificant predictor of RDS, with P 
= 0.14 by Fisher’s exact test.  Finally, neonatal sex was studied.  There were an equal 
number of male and female infants in the study sample, with 105 each.  Five females 
developed neonatal RDS, while three males developed the condition; this variable was 
also found not to be associated with RDS in our population, yielding a p-value of 0.72 by 
Fisher’s exact test.  
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In our total study population of 210 mother-neonate pairs, 40 mothers (19.1%) 
received corticosteroids in the antenatal period while 170 (80.9%) did not.  In the 
population without RDS (n = 202), 33 (16.3%) received steroids while 169 (83.7%) did 
not; in the population complicated by RDS (n = 8), seven (87.5%) received steroids while 
one (12.5%) did not.  Alternatively, 17.5% (7 of 40) pregnancies in the study population 
exposed to antenatal steroids were diagnosed with neonatal RDS, compared with 0.59% 
(1 of 170) of those not exposed.  This was a statistically significant result, with P < 
0.0001 by Fisher’s exact test.  It is known, however, that administration of corticosteroids 
to women in premature labor (spontaneous or planned) has been shown to decrease the 
incidence of neonatal RDS, as well as intraventricular hemorrhage and necrotizing 
enterocolitis (14, 55).  As administration of antenatal corticosteroids is only 
recommended for pregnancies threatening to deliver before 34 weeks of gestation (2, 56), 
and the average gestational age in our study population was 36 weeks, it is likely that 
antenatal corticosteroids in this study were a marker for early gestational age, and not that 















Table 1:  Incidence of Neonatal RDS by Maternal & Neonatal Characteristics 
RDS = respiratory distress syndrome, PG = phosphatidylglycerol band, L/S = lecithin/sphingomyelin 
    Values expressed as n (%), except where *.  * = values expressed as avg (standard dev.) 
    P-values calculated using Chi square or Fisher’s exact test 
 
  
Characteristic Incidence P value 
 Subgroup without RDS 
(n = 202) 
Subgroup with RDS 
(n = 8) 
 
Race 
     White 
     Black 
     Hispanic 
     Asian/South Asian 
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     No diabetes 
     Diet-controlled diabetes 













     No hypertension 
     Chronic hypertension 
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     Steroid Course Given 













3.6 (± 1.1) 
 
 







36.5 (± 1.2) 
 






31.0 (± 6.0) 
 
 




Odds ratios (ORs) were calculated for the variables of interest in this study – 
gestational age and lecithin/sphingomyelin ratio – as well as other commonly cited 
predictors of neonatal RDS, and are shown in Table 2.  Both gestational age and L/S ratio 
were significant predictors of RDS, with ORs of 0.40 (95% CI 0.21 - 0.75) and 0.08 
(95% CI 0.02 - 0.42), respectively.  When adjusted for gestational age, the L/S value 
remained significant with an OR of 0.16 (95% CI 0.03 - 0.86) and P = 0.03.  As 
predicted, the OR for administration of antenatal steroids appeared significant (OR 21.5; 
95% CI 2.43 - 190.3), P = 0.005; however, once adjusted for gestational age, steroids did 
not increase the risk of neonatal RDS (OR 6.83; 95% CI 0.64 - 72.5), P = 0.11.  The 
presence of the phosphatidylglycerol (PG) band also predicted a decreased risk of 
neonatal RDS (OR 0.05; 95% CI 0.01 - 0.42) with P = 0.006, yet once adjusted for 
gestational age the PG band became insignificant in our population (OR 0.11; 95% CI 
0.01 - 1.14), P = 0.06.  Finally, ORs for African-American race, male sex of the neonate, 
and complication of PPROM were found not to predict neonatal RDS.  While the data 
was inestimable for calculating true ORs for maternal tobacco use, preeclampsia, and 
insulin-requiring diabetes, the Chi-square and Fisher’s exact tests reported above 
indicated that these variables were also not associated with RDS in our study sample, 








  Table 2:  Odds Ratio for Logistic Regression Modeling of Neonatal Respiratory Distress Syndrome 
L/S = lecithin/sphingomyelin, PG = phosphatidylglycerol, GA = gestational age, DM = diabetes 
mellitus, PPROM = preterm premature rupture of membranes,  * = statistical significance (p < 0.05),   
£ = adjusted for gestational age, ¥ = compared to all other races, †=change in risk for each 1 week 
increment in gestational age or 1 unit increase in L/S ratio. 
 
 
 The data relating gestational age and lecithin/sphingomyelin ratio – the two 
significant variables in our study – were utilized to derive a predictive equation showing 
the probability of neonatal respiratory distress syndrome.  Equation 2 shows Equation 1 
rearranged to solve for the probability of RDS:   






















The results are displayed in Table 3.  At each week of gestation from 26 weeks, the L/S 
cutoffs are shown with a corresponding risk of neonatal RDS.  Bolded values represent a 
probability of neonatal RDS approximating 0.100, or 10%. 
                                                               Odds Ratio                                               Adjusted Odds Ratio£ 
                                                 (95% Confidence Interval)               P             (95% Confidence Interval)             P 
Gestational Age (wk) †                      0.40 (0.21 – 0.75)            *  0.005                           ---- 
L/S Ratio †                                         0.08 (0.02 – 0.42)            *  0.003                 0.16 (0.03 – 0.86)                * 0.03 
PG Band                                             0.05 (0.01 – 0.42)            *  0.006                 0.11 (0.01 – 1.14)                   0.06 
Antenatal Steroids                              21.5 (2.43 – 190.3)          *  0.005                 6.83 (0.64 – 72.5)                   0.11 
African American race¥                      0.60 (0.07 – 5.37)                0.65                   0.87 (0.08 – 9.45)                  0.91 
Male Infant                                         0.62 (0.14 – 2.85)                0.54                   1.87 (0.25 – 13.8)                  0.54 
PPROM                                              3.93 (0.31 – 49.1)                0.29                   0.45 (0.01 – 16.9)                  0.67 
Smoking                                             --- Inestimable ---           
Preeclampsia                                      --- Inestimable --- 
DM requiring insulin                         --- Inestimable --- 
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Table 3: Predicted Probability of Neonatal Respiratory Distress Syndrome by Gestational Age and  








































































































































































































































































































































































































































































Values are expressed as odds ratios. 






 The timing of a delivery remains a difficult and highly debated topic within the field 
of obstetrics.  Clinical providers must weigh risks and benefits to both mother and baby 
when faced with the possibility of a preterm delivery.  Given what is known about fetal 
pulmonary development, underdeveloped lungs and respiratory complications including 
neonatal RDS are some of the most significant risks of prematurity.  Data showing that 
the incidence of respiratory distress syndrome declines significantly as mothers approach 
full term encourages obstetricians to prolong gestation, avoid early elective deliveries, 
and tocolyze in cases of preterm labor long enough to administer a course of antenatal 
steroids.  However in some cases – when there is danger to the mother or child – delivery 
is the safest option.  Clinical judgment remains the critical factor in assessing these 
situations case by case; amniotic fluid analysis for fetal lung maturity can aid these 
decisions when used properly. 
Since its development in the early 1970’s, the lecithin/sphingomyelin ratio has been 
used to help predict fetal lung maturity.  Institutions generally use a threshold for 
maturity of 2.0 or 2.5; this threshold has not changed appreciably over the years.  What 
complicates the use of such a cutoff is the fact that the incidence of RDS decreases with 
increasing gestational age, which our data supports.  When the incidence of a disease 
changes over a short time course, e.g. toward the end of gestation, a screening test with 
one defined cutoff value is bound to have significant false-positives and false-negatives 
and variable predictive power (57).  Fetal lung maturity studies including the L/S ratio 
generally perform well for ruling out RDS (predicting absence of disease), while falling 
short in terms of ruling in RDS (predicting presence of disease).  Still studies have shown 
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that neonatal morbidity can occur despite “mature” lung indices (37, 38), reminding us of 
the need for improvement in the interpretation of these tests.   
Gestational age-specific probabilities of RDS have recently been determined for the 
TDx-FLM II surfactant-to-albumin ratio assay (39-41).  Our analysis offers a similar 
gestational age-specific risk of RDS for the lecithin/sphingomyelin ratio, the first-line test 
in many institutions.  By modeling the odds of RDS using multivariate logistic regression 
based on our data, a probability of RDS around 10% was found at an L/S value of 3.6 at 
32 weeks, 2.8 at 34 weeks, 1.8 at 36 weeks, and 1.4 at term (37 weeks or greater).  This 
shows that in a frequently critical window for decision making regarding preterm 
delivery, 32 to 37 weeks of gestation, the L/S value conferring the same probability of 
RDS ranges from 3.6 down to 1.4; this significant variation supports the need for an 
algorithm like this one, as opposed to a single cutoff of 2.0. 
Above 38 weeks, an L/S ratio as low as 1.0 would still confer less than 10% 
probability of RDS, although such a result would be uncommon.  This reflects the finding 
that neonatal respiratory distress is uncommon at such a late gestational age, and 
therefore risk is low regardless of the L/S value.  At the other end of the spectrum in 
cases of very early gestation, a probability of RDS as low as 10% is not yielded by our 
algorithm.  Even at 31 weeks, an L/S ratio of 3.6 yields a probability of RDS 
approximating 25% with our model.  The lowest gestational age at which we have data, 
26 weeks, yields a probability of RDS of 97-99% irrespective of the L/S ratio; again this 
reflects the trend that neonatal respiratory distress is a disease of underdevelopment with 
higher rates of incidence at low gestational age.  Based on our table, assessing fetal lung 
 33
maturity with the L/S ratio before 28-29 weeks may have limited utility, as the likelihood 
of acquiring a reassuring test result would be low. 
The main strength of our study was also somewhat of a limitation.  Requiring that 
only mother-neonate pairs delivering within 72 hours of amniocentesis for fetal lung 
maturity ensured that the L/S ratio and the neonatal outcome were temporally related, and 
that information could be gleaned from the assay as a predictor for fetal pulmonary status.  
However, a test-to-delivery interval greater than 72 hours also turned out to be our most 
common cause for exclusion, ruling out 158 mothers from inclusion in the study and 
limiting our total number of cases.  The most significant weakness in the study was the 
low number of neonates with respiratory distress syndrome in our study population.  With 
only 8 cases in our sample, the confidence intervals surrounding our predictions for 
probability of RDS in Table 3 are wide.  Thus more data may be needed before these 
values are used to guide clinical practice and decision making regarding timing of 
delivery.  The precision of the regression model would be improved with additional data 
to increase the number of cases of RDS.   
Nevertheless, our results show that both the lecithin/sphingomyelin ratio and 
gestational age were significant predictors of neonatal respiratory distress in our 
population, and that the L/S ratio remained a significant predictor when adjusted for 
gestational age.  Furthermore the trend according to the logistic regression analysis 
displayed in Table 3 is clear.  The L/S cutoff for a probability of RDS around 10% ranges 
from 1.4 to 3.6 between 32 and 37 weeks of gestation.  The probability of RDS is not 
accurately represented by a single threshold of 2.0, but instead can be more accurately 
determined by a moving threshold based on the gestational age. 
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Aside from gestational age and the L/S ratio, several maternal-fetal characteristics 
may influence the risk of a given fetus developing RDS; these include maternal race (58), 
antenatal tobacco use (59), preeclampsia (60), and diabetes mellitus (61), among others.  
These variations in the host environment may affect fetal cortisol levels, impacting the 
progression of fetal lung maturation (12).  In this study, we included data on maternal age, 
maternal race, tobacco use, presence or absence of preeclampsia, chronic hypertension, 
PPROM, diabetes, and neonatal sex as possible characteristics that may affect the 
prediction of RDS.  Despite the evidence that suggests that these factors do modify the 
risk of neonatal respiratory distress, this did not prove to be the case in our study 
population.  This may be partially due to the small number of cases of RDS, which make 
it difficult to establish definitive trends and variations.  However it is also likely that the 
effects of these characteristics factor less significantly into the overall prediction of lung 
maturity when compared to gestational age and fetal lung maturity assays. 
As discussed briefly in the results, the administration of antenatal steroids was the 
only other significant predictor of RDS in our study; however once adjusted for 
gestational age, these results were no longer statistically significant.  This is likely due to 
the fact that the average gestational age in our sample was 36 weeks, whereas evidence 
for antenatal corticosteroid therapy has been demonstrated in pregnancies less than 34 
weeks of gestation (2, 56).  Steroid administration in our sample was more of an indicator 
of early gestation, and not an independent predictor of neonatal respiratory distress.  
Additional data with a broader range of gestational ages would allow further analysis 
regarding the role of antenatal steroids in the prediction of neonatal RDS using our 
prediction equation. 
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In conclusion, this analysis offers a gestational age- and test- specific algorithm for 
determining the probability of neonatal RDS throughout pregnancy.  While additional 
data is needed to increase the precision of the regression model, these initial results show 
a clear trend in the gestational age-dependent L/S cutoffs when predicting neonatal 
respiratory distress.  We hope that our data will contribute to the growing body of 
evidence that prediction of fetal lung maturity is not a dichotomous endeavor, but rather 
the evaluation of a continuum of risk dependent on gestational age, biochemical assays 
including the L/S ratio, and clinical factors.  As has always been the case, risks and 
benefits must be weighed.  For conditions placing the mother or fetus at risk, such as 
severe preeclampsia or chorioamnionitis, immediate delivery may be indicated regardless 
of gestational age or lecithin/sphingomyelin ratio.  However in cases where urgency is 
less of an issue, an accurate assessment of fetal pulmonary status and probability of RDS 
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